Literature DB >> 36258196

Identification of castration-dependent and -independent driver genes and pathways in castration-resistant prostate cancer (CRPC).

Yan Li1, Hui Shi2, Zhenjun Zhao2, Minghui Xu3.   

Abstract

BACKGROUND: Prostate cancer (PCa) is one of the most diagnosed cancers in the world. PCa inevitably progresses to castration-resistant prostate cancer (CRPC) after androgen deprivation therapy treatment, and castration-resistant state means a shorter survival time than other causes. Here we aimed to define castration-dependent and -independent diver genes and molecular pathways in CRPC which are responsible for such lethal metastatic events.
METHODS: By employing digital gene expression (DGE) profiling, the alterations of the epididymal gene expression profile in the mature and bilateral castrated rat were explored. Then we detect and characterize the castration-dependent and -independent genes and pathways with two data set of CPRC-associated gene expression profiles publicly available on the NCBI.
RESULTS: We identified 1,632 up-regulated and 816 down-regulated genes in rat's epididymis after bilateral castration. Differential expression analysis of CRPC samples compared with the primary PCa samples was also done. In contrast to castration, we identified 97 up-regulated genes and 128 down-regulated genes that changed in both GEO dataset and DGE profile, and 120 up-regulated genes and 136 down-regulated genes changed only in CRPC, considered as CRPC-specific genes independent of castration. CRPC-specific DEGs were mainly enriched in cell proliferation, while CRPC-castration genes were associated with prostate gland development. NUSAP1 and NCAPG were identified as key genes, which might be promising biomarkers of the diagnosis and prognosis of CRPC.
CONCLUSION: Our study will provide insights into gene regulation of CRPC dependent or independent of castration and will improve understandings of CRPC development and progression.
© 2022. The Author(s).

Entities:  

Keywords:  Castration-resistant prostate cancer (CRPC); Cell cycle; Cell proliferation; Differentially expressed genes (DEGs); Prostate gland development

Mesh:

Substances:

Year:  2022        PMID: 36258196      PMCID: PMC9580185          DOI: 10.1186/s12894-022-01113-5

Source DB:  PubMed          Journal:  BMC Urol        ISSN: 1471-2490            Impact factor:   2.090


  41 in total

Review 1.  A history of prostate cancer treatment.

Authors:  Samuel R Denmeade; John T Isaacs
Journal:  Nat Rev Cancer       Date:  2002-05       Impact factor: 60.716

2.  NUSAP1 expression is upregulated by loss of RB1 in prostate cancer cells.

Authors:  Catherine A Gordon; Zulfiqar G Gulzar; James D Brooks
Journal:  Prostate       Date:  2015-01-13       Impact factor: 4.104

3.  RefilinB (FAM101B) targets filamin A to organize perinuclear actin networks and regulates nuclear shape.

Authors:  Olivia Gay; Benoît Gilquin; Fumihiko Nakamura; Zandra A Jenkins; Rosannah McCartney; Deborah Krakow; Alexandre Deshiere; Nicole Assard; John H Hartwig; Stephen P Robertson; Jacques Baudier
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-27       Impact factor: 11.205

Review 4.  Emerging Variants of Castration-Resistant Prostate Cancer.

Authors:  Panagiotis J Vlachostergios; Loredana Puca; Himisha Beltran
Journal:  Curr Oncol Rep       Date:  2017-05       Impact factor: 5.075

5.  AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.

Authors:  Emmanuel S Antonarakis; Changxue Lu; Hao Wang; Brandon Luber; Mary Nakazawa; Jeffrey C Roeser; Yan Chen; Tabrez A Mohammad; Yidong Chen; Helen L Fedor; Tamara L Lotan; Qizhi Zheng; Angelo M De Marzo; John T Isaacs; William B Isaacs; Rosa Nadal; Channing J Paller; Samuel R Denmeade; Michael A Carducci; Mario A Eisenberger; Jun Luo
Journal:  N Engl J Med       Date:  2014-09-03       Impact factor: 91.245

6.  EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

Authors:  Nicolas Mottet; Joaquim Bellmunt; Michel Bolla; Steven Joniau; Malcolm Mason; Vsevolod Matveev; Hans-Peter Schmid; Theo Van der Kwast; Thomas Wiegel; Filiberto Zattoni; Axel Heidenreich
Journal:  Eur Urol       Date:  2011-01-25       Impact factor: 20.096

Review 7.  Metastatic Prostate Cancer: Treatment Options.

Authors:  Vérane Achard; Paul Martin Putora; Aurelius Omlin; Thomas Zilli; Stefanie Fischer
Journal:  Oncology       Date:  2021-11-15       Impact factor: 2.935

Review 8.  Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer.

Authors:  Philip A Watson; Vivek K Arora; Charles L Sawyers
Journal:  Nat Rev Cancer       Date:  2015-11-13       Impact factor: 60.716

9.  Stromal transforming growth factor-beta signaling mediates prostatic response to androgen ablation by paracrine Wnt activity.

Authors:  Veronica R Placencio; Ali-Reza Sharif-Afshar; Xiaohong Li; Hongxia Huang; Consolate Uwamariya; Eric G Neilson; Michael M Shen; Robert J Matusik; Simon W Hayward; Neil A Bhowmick
Journal:  Cancer Res       Date:  2008-06-15       Impact factor: 12.701

10.  NCAPG Promotes The Proliferation Of Hepatocellular Carcinoma Through PI3K/AKT Signaling.

Authors:  Chengwu Gong; Jiyuan Ai; Yun Fan; Jun Gao; Weiwei Liu; Qian Feng; Wenjun Liao; Linquan Wu
Journal:  Onco Targets Ther       Date:  2019-10-16       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.